Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

2016 ◽  
Vol 23 (3) ◽  
pp. 395-402 ◽  
Author(s):  
Egil Røsjø ◽  
Andreas Lossius ◽  
Nada Abdelmagid ◽  
Jonas C Lindstrøm ◽  
Margitta T Kampman ◽  
...  
Keyword(s):  
Vitamin D ◽  
Epstein Barr Virus ◽  
High Dose ◽  
Oral Vitamin ◽  
Barr Virus ◽  
Relapsing Remitting ◽  
Dose Oral ◽  
Epstein Barr ◽  
Antibody Levels ◽  
Relapsing Remitting Multiple Sclerosis

Background: Elevated antibody levels against Epstein–Barr virus (EBV) and a poor vitamin D status are environmental factors that may interact in relapsing-remitting multiple sclerosis (RRMS) aetiology. Objectives: To examine effects of high-dose oral vitamin D3 supplementation on antibody levels against EBV nuclear antigen 1 (EBNA1) in RRMS. Methods: Serum 25-hydroxyvitamin D3 (25(OH)D) and immunoglobulin G antibody levels against EBNA1 (whole protein and amino acid 385–420 fragment), EBV viral capsid antigen (VCA), cytomegalovirus (CMV) and varicella zoster virus (VZV) were measured in 68 RRMS patients enrolled in a 96-week randomised double-blinded placebo-controlled clinical trial of oral vitamin D3 supplementation (20,000 IU/week) (NCT00785473). Results: The mean 25(OH)D level more than doubled in the vitamin D group and was significantly higher than in the placebo group at study conclusion (123.2 versus 61.8 nmol/L, p < 0.001). Compared to the placebo group, both anti-EBNA1 protein and fragment antibody levels decreased in the vitamin D group from baseline to week 48 ( p = 0.038 and p = 0.004, respectively), but not from baseline to week 96. Vitamin D3 supplementation did not affect antibodies against VCA, CMV or VZV. Conclusion: The results indicate that high-dose oral vitamin D3 supplementation can affect humoral immune responses against the latent EBV antigen EBNA1 in RRMS.

Multiple sclerosis-associated retrovirus, Epstein-Barr virus, and vitamin D status in patients with relapsing remitting multiple sclerosis

2017 ◽  
Vol 89 (7) ◽  
pp. 1309-1313 ◽  
Author(s):  
Aliehossadat Mostafa ◽  
Somayeh Jalilvand ◽  
Zabihollah Shoja ◽  
Ahmad Nejati ◽  
Shohreh Shahmahmoodi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Epstein Barr Virus ◽  
Vitamin D Status ◽  
Barr Virus ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Epstein Barr ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Treatment of Infectious Mononucleosis with High Dose Vitamin D3 in Three Cases

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Schwalfenberg GK ◽  
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Infectious Mononucleosis ◽  
Epstein Barr Virus ◽  
Fungal Infections ◽  
High Dose ◽  
Significant Morbidity ◽  
Barr Virus ◽  
Epstein Barr ◽  
High Dose Vitamin

Infectious mononucleosis often results in significant morbidity and disability lasting up to six months. It is known that vitamin D induces cathelicidin production that can rapidly responds to some viral, bacterial and fungal infections. The Epstein Barr virus is able to block the vitamin D receptor thus blocking the ability to fight this infection. This article presents three cases, which responded quickly to loading doses of vitamin D (150,000-200,000 IU) followed by a month of 10,000IU daily.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients

2016 ◽  
Vol 23 (6) ◽  
pp. 1064-1070 ◽  
Author(s):  
S. Wergeland ◽  
K.-M. Myhr ◽  
K. I. Løken-Amsrud ◽  
A. G. Beiske ◽  
K. S. Bjerve ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Prospective Cohort ◽  
Epstein Barr Virus ◽  
Virus Antibody ◽  
Barr Virus ◽  
Epstein Barr ◽  
Multiple Sclerosis Patients ◽  
Antibody Levels

scholarly journals Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis

2017 ◽  
Vol 24 (10) ◽  
pp. 1280-1287 ◽  
Author(s):  
Linda Rolf ◽  
Anne-Hilde Muris ◽  
Amandine Mathias ◽  
Renaud Du Pasquier ◽  
Inga Koneczny ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Underlying Mechanism ◽  
Cytotoxic T Cell ◽  
High Dose ◽  
Cell Responses ◽  
Relapsing Remitting ◽  
Cytotoxic T Cell Responses ◽  
Antibody Levels ◽  
Relapsing Remitting Multiple Sclerosis

Background: Epstein–Barr virus (EBV) infection and vitamin D insufficiency are potentially interacting risk factors for multiple sclerosis (MS). Objectives: To investigate the effect of high-dose vitamin D3 supplements on antibody levels against the EBV nuclear antigen-1 (EBNA-1) in patients with relapsing-remitting multiple sclerosis (RRMS) and to explore any underlying mechanism affecting anti-EBNA-1 antibody levels. Methods: This study utilized blood samples from a randomized controlled trial in RRMS patients receiving either vitamin D3 (14,000 IU/day; n = 30) or placebo ( n = 23) over 48 weeks. Circulating levels of 25-hydroxyvitamin-D, and anti-EBNA-1, anti-EBV viral capsid antigen (VCA), and anti-cytomegalovirus (CMV) antibodies were measured. EBV load in leukocytes, EBV-specific cytotoxic T-cell responses, and anti-EBNA-1 antibody production in vitro were also explored. Results: The median antibody levels against EBNA-1, but not VCA and CMV, significantly reduced in the vitamin D3 group (526 (368–1683) to 455 (380–1148) U/mL) compared to the placebo group (432 (351–1280) to 429 (297–1290) U/mL; p = 0.023). EBV load and cytotoxic T-cell responses were unaffected. Anti-EBNA-1 antibody levels remained below detection limits in B-cell cultures. Conclusion: High-dose vitamin D3 supplementation selectively reduces anti-EBNA-1 antibody levels in RRMS patients. Our exploratory studies do not implicate a promoted immune response against EBV as the underlying mechanism.

Sign in / Sign up

Export Citation Format

Share Document